About Shield Bio
Shield Bio is a company based in San Jose (United States) founded in 2016 by Fred Turner. It operates as a B2B. Shield Bio has raised $10.26 million across 4 funding rounds from investors including Y Combinator and Andreessen Horowitz. Shield Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter San Jose, United States
- Founders Fred Turner
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10.26 M (USD)
in 4 rounds
-
Latest Funding Round
$5.34 M (USD), Series A
May 11, 2018
-
Investors
Y Combinator
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Shield Bio
Shield Bio has successfully raised a total of $10.26M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.34 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Shield Bio
Shield Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Y Combinator and Andreessen Horowitz.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are accelerated via funding and educational programs.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
|
Locked | Locked | Locked |
Investor details for Shield Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Shield Bio
Investment portfolio details for Shield Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Shield Bio
Detailed financials for Shield Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Shield Bio Comparisons
Peer comparison for Shield Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Shield Bio
Shield Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
Detailed competitors of Shield Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Shield Bio
Complete news archive for Shield Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shield Bio
Shield Bio was founded in 2016.
Shield Bio is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Fred Turner is the current CEO of Shield Bio. They have also founded this company.
Shield Bio is a funded company, having raised a total of $10.26M across 4 funding rounds to date.
Shield Bio, led by Fred Turner as Co-Founder, CEO, specializes in providing healthcare solutions, advancing biotech innovations, drug development, and infectious diseases. Provides technology for developing precision drugs to treat infectious diseases. The team drives innovation, quality service, and sustainable practices to achieve excellence and client satisfaction.
Shield Bio's top competitors include Spark Therapeutics, BridgeBio and Cepheid.
Shield Bio has 2 investors. Key investors include Y Combinator, and Andreessen Horowitz.